531015 VENMAX

Venmax Drugs & Pharmaceuticals Share Price

 

 

Start SIP in VENMAX

Start SIP
Venmax Drugs & Pharmaceuticals live price: ₹25.6. It opened at ₹24 vs previous close ₹26; intraday high/low: ₹26/₹23. The 50 & 200 DMA stand at ₹25.56/₹25.22.

Venmax Drugs & Pharmaceuticals Performance

  • Today's Low
  • ₹23
  • Today's High
  • ₹26
  • 52 Week Low
  • ₹19
  • 52 Week High
  • ₹37
  • Open Price₹24
  • Previous Close₹26
  • Volume465
  • 50 DMA₹25.56
  • 100 DMA₹25.92
  • 200 DMA₹25.22

Investment Returns

  • Over 1 Month + 5.79%
  • Over 3 Month -0.54%
  • Over 6 Month + 27.05%
  • Over 1 Year -15.4%

Smart Investing Starts Here Start SIP with Venmax Drugs & Pharmaceuticals for Steady Growth!

Invest Now

Venmax Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 15.4
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 13
  • P/B Ratio
  • 2.3
  • Average True Range
  • 3.33
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.1
  • RSI
  • 46.12
  • MFI
  • 14.3

Venmax Drugs & Pharmaceuticals Financials

Venmax Drugs & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹25.60
-0.4 (-1.54%)
pointer
  • Bearish Moving Average 5
  • Bullish Moving Average 11
  • 20 Day
  • ₹25.27
  • 50 Day
  • ₹25.56
  • 100 Day
  • ₹25.92
  • 200 Day
  • ₹25.22

Resistance and Support

24.63 Pivot Speed
  • R3 28.47
  • R2 27.23
  • R1 25.87
  • S1 23.27
  • S2 22.03
  • S3 20.67

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Venmax Dg.And Pharms. has an operating revenue of Rs. 4.41 Cr. on a trailing 12-month basis. An annual revenue growth of 830% is outstanding, Pre-tax margin of -2% needs improvement, ROE of -0% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. It is currently FORMING a base in its weekly chart and is trading around 22% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 75 which is FAIR indicating the recent price performance, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 41 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Venmax Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-07 Quarterly Results
2025-11-12 Quarterly Results
2025-09-02 Amalgamation & A.G.M.
2025-08-16 Others Inter alia, to consider and approve 1. Allotment of Equity Shares pursuant to conversion of Convertible Equity Share Warrants.
2025-07-23 Quarterly Results

Venmax Drugs & Pharmaceuticals F&O

Venmax Drugs & Pharmaceuticals Shareholding Pattern

15.14%
0%
64.25%
20.61%

Venmax Drugs & Pharmaceuticals FAQs

Venmax Drugs & Pharmaceuticals share price is ₹25 As on 04 April, 2026 | 14:19

The Market Cap of Venmax Drugs & Pharmaceuticals is ₹13.4 Cr As on 04 April, 2026 | 14:19

The P/E ratio of Venmax Drugs & Pharmaceuticals is 15.4 As on 04 April, 2026 | 14:19

The PB ratio of Venmax Drugs & Pharmaceuticals is 2.3 As on 04 April, 2026 | 14:19

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23